Intellectual Property Issues Under The Trans-Pacific Partnership | Biosimilar Development
Knobbe Martens attorneys Sheila Swaroop, Joseph Reisman and Scott Seeley recently authored "Intellectual Property Issues Under The Trans-Pacific Partnership," which was featured in the publication Biosimilar Development.
Excerpt: On November 5, 2015, after five years of largely secret negotiations, the parties to the Trans-Pacific Partnership (TPP) published the official language of this agreement. The TPP is a multi-national trade agreement between Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, Vietnam, and the United States. The stated goals of the TPP are to liberalize trade among member nations and to equalize regulatory restrictions and intellectual property (IP) protections among the parties. This article highlights three intellectual property provisions in the TPP that are pertinent to biopharmaceutical companies.